Search

Reports that U.S. Food and Drug Administration (FDA) has approved Roche's microarray-based test., the AmpliChip CYP450 Test, for diagnostic use in the United States. Test procedure; Key genetic regions encoding the enzymes of the cytochrome P450.

Reports on the partnership of Roche Diagnostics and its suppliers to raise funds for research concerning diabetes and obesity. Amount of funds raised by the partnership; Statistics on the annual cost of diabetes in medical expenditures and lost productivity; Efforts of the Richard and Susan Smith Family Foundation in Boston, Massachusetts in supporting research projects in diabetes.

Cites the announcement by Roche Diagnostics of the approval by the U.S. Food and Drug Administration's Blood Products Advisory Committee support for the licensing of Roche's COBAS Amplicreen HBV Test as a screening tool for the detection of hepatitis B in donated whole blood.

Reports that the U.S. Food and Drug Administration's Blood Products Advisory Committee has approved Roche Diagnostics' COBAS AmpliScreen hepatitis B virus test for donated blood.

Reports on the recognition of the Entelos PhysioLab technology for winning the Best Practices Awards in the U.S. Assessment on the quality of the device; Usability of the product in identifying insulin sensitivity in various diabetic patients; Product specifications.

Announces the recognition given by the "Training" magazine to Roche Diagnostics Corp. for excellence in personnel management in the U.S. Aim of fostering people's learning, development and relationships within the company; Investment in training and development programs; Launch of the learning system myLEARNINGlink.

Roche Diagnostics Corp. and Diagnostic Products Corp. (DPC) announced that DPC has been granted a nonexclusive license under patent rights of Roche Diagnostics relating to the development, manufacture and marketing of immunoassays that detect a key marker of congestive heart failure, N-terminal prohormone brain natriuretic peptide, (NT-proBNP). NT-proBNP is a unique diagnostic and management tool, and licensing it broadly will help to maximize the benefit of this product to patients, the medical community, and shareholders.

Reports on the launch of the Factor V Leiden Kit and Factor II (Prothrombin) G20210A Kit diagnostic tests from Roche Diagnostics Corp. for its LightCycler real-time polymerase chain reaction instrument in the U.S. Components of the kit; Approval of the Food and Drug Administration to the product; Progress of the clinical testing.

Reports on Surgeon General Richard H. Carmona's launched of the U.S. Department of Health and Human Services' Diabetes Detection Initiative, Finding the Undiagnosed.

Reports on the nationwide recall of Roche Diagnostics Corp. for users of CoaguChek PT test strips use to treat blood clotting. Potential for a packaging defect of the product that will cause false results; Notification of company to all home users of the product; Defect of the product.

Reports on the move of Syn X Pharma Inc. to grant Roche Diagnostics Corp. patent rights of Syn X relating to the development, manufacture and marketing of immunoassays. Terms in the license agreement; Purpose of the immunoassays; Overview on the products of Syn X.

Roche Diagnostics said its TaqScreen West Nile Virus Test has successfully identified a unit of blood with confirmed West Nile virus infection. The infected blood was intercepted at Gulf Coast Regional Blood Center in Houston, Texas, 1 of the 11 clinical trial sites evaluating Roche's new system. This marks the first instance of human West Nile virus infection reported in the United States in 2003. West Nile virus is a mosquito-borne virus that can cause life-threatening illness and death. An estimated 80% of people infected with West Nile virus never show any signs of illness. Nearly all of the remaining 20% experience only mild flu-like symptoms. "People who receive transfusion of blood or blood products may be quite sick and more susceptible to the serious and life threatening complications that can arise from West Nile virus infection.

Roche Diagnostics Corp. said its TaqScreen West Nile Virus Test has successfully identified a unit of blood with confirmed West Nile virus infection. The infected blood was intercepted at Gulf Coast Regional Blood Center in Houston, Texas. The site began screening newly donated blood for West Nile virus on June 18, 2003. With the TaqScreen West Nile Virus Test, Roche introduced the first North American nucleic acid blood screening system to fully automate specimen processing, amplification and detection, important features for testing sites trying to keep up with increased screening requirements. The test uses Roche's highly sensitive polymerase chain reaction technology to detect the genetic material of the virus itself, in blood donated by people who may feel fine.

Reports on the partnership between the American Diabetes Association Research Foundation and Roche Diagnostics in the "Partner for a Cure" fund-raising effort to benefit diabetes and obesity research.

Reports that Roche Diagnostics Corp. has received clearance from the U.S. Food and Drug Administration for the Elecsys Troponin T STAT test as an aid in the differential diagnosis of acute coronary syndrome and for risk stratification in patients with chronic renal failure. Usefulness of the test in the selection of more intensive therapy and intervention in patients with elevated levels of cardiac Tropotin T; Functions of the Elecsys Troponin T test; Potential of Troponin to be used in identifying patients with acute coronary syndromes who may benefit from anti-thrombotic therapy.

Reports on the agreement between Inverness Medical Innovations Inc. and Roche Diagnostics Corp. for the marketing of NT-proBNP. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for marketing of NT-proBNP.

Reports on the grant for the Elecsys proBNP immunoassay from Roche Diagnostics Corp. by the U.S. Food and Drug Administration. Use of the assay in detecting the level of NT-proBNP peptide an an aid in the diagnosis of congestive heart failure (CHF); Clearance of the assay for risk stratification in CHF and in acute coronary syndrome; Significance of the technology to physicians.

Florida's largest blood bank has detected the West Nile virus in a unit of donated blood. The Central Florida Blood Bank finding underscored the need to check donated blood for the virus that can cause potentially dangerous brain infections. The donation was traced to a 36-year-old man from Rockledge in Brevard County who does not have any symptoms of a West Nile infection. Scientists determined in 2002 that West Nile virus, typically transmitted by mosquitoes, can be transferred through blood transfusions, organ transplants and possibly breastfeeding.